Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Finished Goods: 2023-2025

Historic Finished Goods for Iovance Biotherapeutics (IOVA) over the last 1 years, with Mar 2025 value amounting to $15.5 million.

  • Iovance Biotherapeutics' Finished Goods rose 153.30% to $15.5 million in Q1 2025 from the same period last year, while for Mar 2025 it was $15.5 million, marking a year-over-year increase of 153.30%. This contributed to the annual value of $15.0 million for FY2024, which is 224.72% up from last year.
  • According to the latest figures from Q1 2025, Iovance Biotherapeutics' Finished Goods is $15.5 million, which was up 3.55% from $15.0 million recorded in Q4 2024.
  • In the past 5 years, Iovance Biotherapeutics' Finished Goods ranged from a high of $15.5 million in Q1 2025 and a low of $1.1 million during Q2 2023.
  • For the 3-year period, Iovance Biotherapeutics' Finished Goods averaged around $7.9 million, with its median value being $5.5 million (2023).
  • Data for Iovance Biotherapeutics' Finished Goods shows a peak YoY soared of 224.72% (in 2024) over the last 5 years.
  • Quarterly analysis of 3 years shows Iovance Biotherapeutics' Finished Goods stood at $4.6 million in 2023, then surged by 224.72% to $15.0 million in 2024, then spiked by 153.30% to $15.5 million in 2025.
  • Its Finished Goods stands at $15.5 million for Q1 2025, versus $15.0 million for Q4 2024 and $6.1 million for Q1 2024.